The duration and intensity of immunosuppression determine risks. Short-term immunosuppression from IRTs is front-loaded and don't accumulate with time, which is what happens with maintenance DMTs.
This patient with MS is anxious that he may have early secondary progressive MS and rituximab is failing him. He is keen to explore AHSCT. Is this appr…
Trigeminal neuralgia, brief, very painful, electric shock-like episodes in the distribution of the trigeminal nerve is common in people with MS. This n…
I am getting endless questions about when is the best time to have the 3rd and/or booster dose of the COVID-19 vaccine in relation to ocrelizumab infus…
The newsletter addresses the differences between maintenance-escalation disease-modifying therapies and immune reconstitution therapies (IRTs) and why …
When a neurologist thinks alemtuzumab is too risky the question needs to be asked ‘too risky for whom; the neurologist or the patient?’.
What are your priorities in relation to 'Your MS'?Many readers of these Newsletters are highlighting that they haven’t seen their neurologist or a neurologist, for some time now. Many of you sta…
Are you battling to get your nocturnal spasms under control? Are your legs collapsing when you increase the dose of your anti-spastic medication?
See all